25 Or More Amino Acid Residues In Defined Sequence Patents (Class 530/324)
-
Patent number: 8859722Abstract: Disclosed is the cloning, expression and purification of a hemolysin protein and its protein fragments in Anaplasma phagocytophilum. The recombinant hemolysin and its protein fragments are useful in the ELISA detection of anaplasma pathogen. The use of same as a kit for ELISA is also disclosed.Type: GrantFiled: July 30, 2012Date of Patent: October 14, 2014Assignee: Medical Diagnostic Laboratories, LLCInventors: John G. Hoey, Denise P. Dimitrov, Lisa P. Huang, Martin E. Adelson, Eli Mordechai
-
Patent number: 8859492Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.Type: GrantFiled: May 12, 2012Date of Patent: October 14, 2014Assignee: MetalloPharm, LLCInventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
-
Publication number: 20140303084Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.Type: ApplicationFiled: June 9, 2012Publication date: October 9, 2014Applicant: Biogen IDEC MA Inc.Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo
-
Publication number: 20140302070Abstract: In one embodiment, the present invention provides a new isoform of human PD1 (?42PD1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. ?42PD1 does not engage PD-L1/PD-L2, and can induce the production of pro-inflammatory cytokines In one embodiment, ?42PD1 can be used as an intramolecular adjuvant to develop a fusion DNA vaccine for enhancing antigen-specific CD8+ T cell immunity and for prevention of pathogenic infection and/or cancer. In one embodiment, soluble ?42PD1 protein could be a therapeutic target for autoimmune diseases. In other embodiments, proteins or peptides or nucleic acids encoding proteins or peptides containing ?42PD1 could be used as immunogens for developing antibodies binding specifically to ?42PD1. In yet another embodiment, neutralizing antibodies could block s?42PD1 function and accordingly could be used as treatment for autoimmune disorders.Type: ApplicationFiled: April 7, 2014Publication date: October 9, 2014Applicant: The University of Hong KongInventors: Zhiwei Chen, Lin Cheng, Allen Ka Loon Cheung, Jingying Zhou
-
Publication number: 20140303069Abstract: Anti-microbial peptides and methods of use are provided.Type: ApplicationFiled: November 20, 2012Publication date: October 9, 2014Inventors: Guangshun Wang, Biswajit Mishra
-
Publication number: 20140302074Abstract: The present disclosure relates generally to epitopes of an antibody known as PAT-LM1, and methods for using said epitopes.Type: ApplicationFiled: October 29, 2012Publication date: October 9, 2014Inventors: Arndt-Rene Kelter, Frank Hensel, Vic Ilag, Barbara Power, Christopher Garth Hosking
-
Publication number: 20140303078Abstract: Work described herein provides, in one embodiment, a method for increasing proliferation or replication of pancreatic beta cells in a subject in need thereof, comprising administering to said subject an effective amount of an agent that increases the level or activity of hepatocellular carcinoma-associated protein TD26 (TD26), thereby increasing proliferation or replication of pancreatic beta cells. Such an agent may function by, for example, increasing the level of active TD26 in the subject or by increasing the functional activity of TD26 in the subject.Type: ApplicationFiled: June 10, 2012Publication date: October 9, 2014Applicant: President and Fellows of Harvard CollegeInventors: Douglas A. Melton, Peng Yi
-
Publication number: 20140302083Abstract: The present invention relates to isolated Porphyromanas gingivalis polypeptides and nucleotides. The polypeptides include an amino acid sequence selected from the group consisting of: SEQ. ID. NO. 110; SEQ. ID. NO. 111; SEQ. ID. NO. 112; SEQ. ID. NO. 113; SEQ ID NO: 120; SEQ. ID. NO. 123; SEQ. ID. NO. 124; SEQ. ID. NO. 125; SEQ. ID. NO. 130; SEQ. ID. NO. 131; SEQ. ID. NO. 132; SEQ. ID. NO. 133; SEQ. ID. NO. 135; SEQ. ID. NO. 136; SEQ. ID. NO. 137; SEQ. ID. NO. 138; SEQ. ID. NO. 143; SEQ. ID. NO. 144; SEQ. ID. NO. 145; SEQ. ID. NO. 146; SEQ. ID. NO. 147; SEQ. ID. NO. 148; and amino acid sequences at least 95% identical thereto.Type: ApplicationFiled: January 23, 2014Publication date: October 9, 2014Applicants: THE UNIVERSITY OF MELBOURNE, CSL LIMITEDInventors: BRUCE C. ROSS, IAN G. BARR, MICHELLE A. PATTERSON, CATHERINE T. AGIUS, LINDA J. ROTHEL, MAI B. MARGETTS, DIANNA M. HOCKING, ELIZABETH A. WEBB
-
Patent number: 8853150Abstract: Featured herein are non-naturally occurring cytokine domains that can be used, inter alia, to modulate cellular signalling responsive to interleukin-1 receptor I (IL-1 RI), to treat disorders, and to detect and/or bind to cellular receptors, as well as other agents. Exemplary cytokine domains can contain amino acid residues from at least two parental cytokines domains, for example, receptor binding features, surface features, ? strands, and loops from at least two parental cytokines domains.Type: GrantFiled: July 29, 2011Date of Patent: October 7, 2014Assignee: Eleven Biotherapeutics, Inc.Inventors: Thomas M. Barnes, Jinzhao Hou, Bracken M. King
-
Patent number: 8853494Abstract: Disclosed herein are novel variant bacterial cold shock proteins and recombinant DNA for expressing such proteins to produce transgenic plants with enhanced stress tolerance and/or enhanced yield.Type: GrantFiled: August 14, 2009Date of Patent: October 7, 2014Assignee: Monsanto Technology LLCInventors: Christopher P. Bonin, Paolo Castiglioni, Robert L. D'Ordine, Jacqueline E. Heard, Robert M. McCarroll, Sara Salvador, Michael J. Storek
-
Patent number: 8853131Abstract: The invention provides novel scaffold proteins for the display of peptides such as peptide aptamers. The novel scaffold proteins are modifications of Stefin A or STM (a variant of Stefin A) and are useful as scaffold proteins and as display systems.Type: GrantFiled: April 16, 2009Date of Patent: October 7, 2014Assignee: Aptuscan LimitedInventors: Paul Ko Ferrigno, Elisenda Gendra
-
Patent number: 8853490Abstract: Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include amino acid sequences, and variants and fragments thereof, for novel variants of antipathogenic polypeptides generated through DNA shuffling that exhibit improved antipathogenic activity. Polynucleotides that encode the antipathogenic polypeptides are also provided. A method for inducing pathogen resistance in a plant using the polynucleotides disclosed herein is further provided. Compositions comprising an antipathogenic polypeptide or a microorganism comprising an antipathogenic polynucleotide of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Plants, plant cells, seeds, and microorganisms comprising an antipathogenic polynucleotide or polypeptide of the invention are also disclosed.Type: GrantFiled: September 22, 2011Date of Patent: October 7, 2014Assignee: Pioneer Hi Bred International IncInventors: James J. English, Azalea S. Ong, Nasser Yalpani
-
Patent number: 8853165Abstract: The present invention relates to a peptide having bone tissue regeneration capacity and binding to a surface of apatite. More particularly, a peptide is provided having bone tissue regeneration capacity and specifically binding to a surface of apatite mineral, capable of being stably immobilized to the surface of apatite mineral to retain effective activity and exhibit bone regeneration effects for a long time, by linking an amino acid sequence having bone tissue regeneration capacity and an amino acid sequence having apatite-binding capacity to each other to thereby provide a peptide having both bone-forming effects and binding capacity to the surface of apatite mineral. A composition for bone tissue regeneration containing the peptide is further provided.Type: GrantFiled: March 9, 2011Date of Patent: October 7, 2014Assignee: Nano Intelligent Biomedical Engineering Corporation Co., Ltd.Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Sang Hoon Rhee, Jue-Yeon Lee
-
Publication number: 20140294871Abstract: The present invention relates to antimicrobial peptides, isolated and purified from extracts of tilapia (Oreochromis niloticus) gills. Such peptides may be produced by chemical synthesis or by expression in heterologous systems, such as bacteria and yeasts, by conventional molecular biology techniques. These peptides show antimicrobial activity against various organisms, including Gram positive bacteria, Gram negative bacteria, fungi and viruses. The invention also includes compositions to for controlling pathogens comprising these antimicrobial peptides. The use of such peptides in vaccine preparations, as molecular adjuvants, is also part of the invention.Type: ApplicationFiled: October 1, 2012Publication date: October 2, 2014Applicant: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIAInventors: Jannel Acosta Alba, Mario Pablo Estrada Garcia
-
Publication number: 20140296479Abstract: The present invention is characterized by a D-Aptamer-Like Peptide (D-Aptide) or retro-inverso Aptide which specifically binds to a target comprising: (a) a structure stabilizing region comprising parallel, antiparallel or parallel and antiparallel D-amino acid strands with interstrand noncovalent bonds; and (b) a target binding region I and a target binding region II comprising randomly selected n and m D-amino acids, respectively, and coupled to both ends of the structure stabilizing region. The D-Aptide or retro-inverso Aptide has the sequence of the same or opposite direction to L-Aptide, wherein the stability to proteases is improved while maintaining the affinity to a target compared with L-Aptide. The D-Aptide of the present invention has substantially the same target affinity and a remarkably improved stability compared with L-Aptide which is different from a general technical knowledge.Type: ApplicationFiled: April 6, 2012Publication date: October 2, 2014Applicant: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Sang-Yong Jon, Sung-Hyun Kim
-
Publication number: 20140296131Abstract: The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration.Type: ApplicationFiled: June 9, 2014Publication date: October 2, 2014Applicant: NOVO NORDISK A/SInventors: Jane Spetzler, Lauge Schaeffer, Jesper Lau, Janos T. Kodra, Kjeld Madsen, Patrick W. Garibay, Jacob Kofoed, Steffen Reedtz-Runge, Henning Thoegersen, Ingrid Pettersson
-
Publication number: 20140294942Abstract: In certain embodiments this invention provides novel antiviral peptide(s) that are effective against positive sense RNA viruses that have an internal ribosome entry site (IRES). The peptide(s) can be used to inhibit propagation of such viruses and thereby provide a effective modality for the treatment of infections such as hepatitis C, and the like.Type: ApplicationFiled: September 6, 2012Publication date: October 2, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Samuel Wheeler French, Ronik Khachatoorian, Piotr Pawel Ruchala
-
Publication number: 20140296480Abstract: Among the fewer than 10 proteins primarily secreted by the species Lactobacillus plantarum, there is one of 30 kDa that contains an internal fragment without cleavage sites for the most important intestinal proteases and characterized by having a serine and threonine content of at least 50%. The genetic information encoded in this fragment, designated ST peptide, has been used for producing and purifying said peptide, thus making it possible to conduct various tests in vitro. To summarize, the ST peptide is considered to promote the process of immunologic ignorance of our gastrointestinal immune system toward the commensal bacteria of our gastrointestinal tract, thus favoring the mechanisms of oral tolerance. Therefore the ST peptide could be used in immunotherapy, especially in the context of certain autoimmune diseases and certain inflammatory diseases.Type: ApplicationFiled: September 7, 2012Publication date: October 2, 2014Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Borja Sanchez Garcia, Abelardo Margolles Barros, David Bernardo Ordiz, Stella C. Knight, Hafid Omar
-
Publication number: 20140296091Abstract: There is provided a diagnostic reagent for use in the detection of M. bovis or M. tuberculosis infection in an animal, comprising a peptide which has an epitope from Mycobacterium bovis hypothetic protein Mb3645c (SEQ ID NO: 1) or an epitope from a polypeptide having at least 76% identity with SEQ ID NO: 1.Type: ApplicationFiled: February 21, 2014Publication date: October 2, 2014Inventors: Hans Martin Vordermeier, Benjamin Sidders, Neil Graham Stoker, Katie Ewer
-
Publication number: 20140296161Abstract: A novel Tistrella mobilis strain having Accession Deposit Number NRRL B-50531 is provided. A method of producing a didemnin precursor, didemnin or didemnin derivative by using the Tistrella mobilis strain, and the therapeutic composition comprising at least one didemnin or didemnin derivative produced from the strain or modified strain thereof are also provided.Type: ApplicationFiled: September 21, 2012Publication date: October 2, 2014Applicant: King Abdullah University of Science and TechnologyInventors: Pei-Yuan Qian, Ying Sharon Xu, Pok-Yui Lai
-
Publication number: 20140296132Abstract: The present invention provides polypeptides, compositions thereof, and methods for use of the polypeptides in treating bacterial infection and for use as disinfectants.Type: ApplicationFiled: November 1, 2012Publication date: October 2, 2014Applicant: Arizona Board of Regents of behalf of Arizona State UniversityInventors: Stephen Johnston, Valeriy Domenyuk, Chris Diehnelt
-
Publication number: 20140296434Abstract: The present invention relates to chromatography matrices including ligands based on one or more domains of immunoglobulin-binding proteins such as, Staphylococcus aureus Protein A (SpA), as well as methods of using the same.Type: ApplicationFiled: June 6, 2014Publication date: October 2, 2014Inventors: Shari Spector, Robert Smith, Joe Orlando, Nanying Bian
-
Publication number: 20140294918Abstract: Chemoattractant polypeptide compounds for progenitor cells and compositions and drug products comprising the compounds are provided herein. Methods for attracting progenitor cells to a location in or on a patient also are provided along with methods of growing and repairing bone.Type: ApplicationFiled: April 9, 2014Publication date: October 2, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Vineet Agrawal, Stephen F. Badylak, Scott A. Johnson, Stephen Tottey
-
Publication number: 20140294877Abstract: The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.Type: ApplicationFiled: March 4, 2014Publication date: October 2, 2014Applicant: CUREVAC GMBHInventors: Patrick BAUMHOF, Thomas SCHLAKE
-
Publication number: 20140296146Abstract: The present invention relates to the field of blood clotting. Specifically, the invention relates to particular inhibitors of artificial activation of the blood clotting process through contact with foreign surfaces.Type: ApplicationFiled: August 20, 2012Publication date: October 2, 2014Applicants: Synapse B.V., Universiteit MaastrichtInventors: Tilman Mathias Hackeng, Dennis Peter Leonardo Suijlen, Hendrik Coenraad Hemker, Rafael Jesus Apitz-Castro
-
Patent number: 8846624Abstract: In an embodiment, a number of synthetic protein triblock copolymers are provided comprising first and second end hydrophobic blocks separated by a central hydrophilic block. In particular, the synthetic proteins are elastin-mimetic proteins having improved mechanical characteristics and related methods of making the proteins with the capability of providing precise control over the mechanical properties. Provided are proteins used in a number of medical devices such as artificial blood vessels, shunts, stents or as embolic agents in situations where it is desired to stop or reduce blood flow or pressure in a localized region.Type: GrantFiled: September 11, 2007Date of Patent: September 30, 2014Assignee: Emory UniversityInventors: Elliot L. Chaikof, Vincent P. Conticello
-
Patent number: 8846614Abstract: A process for the production of pramlintide, a 37-mer peptide, is provided. The synthesis provides a high yield synthesis of the peptide in relatively pure form. Further purification can be achieved by preparative HPLC.Type: GrantFiled: August 22, 2012Date of Patent: September 30, 2014Assignee: USV LimitedInventors: Nikhil Umesh Mohe, Praful Shamrao Chavre, Bharti Prabhakarrao Deshmukh, Chandrakesan Muralidharan, Lester John Lobo, Digamber Shripati Pawar, Divya Lal Saksena
-
Patent number: 8846625Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: GrantFiled: March 11, 2013Date of Patent: September 30, 2014Assignee: 1149336 Ontario Inc.Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
-
Patent number: 8846623Abstract: Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.Type: GrantFiled: October 25, 2011Date of Patent: September 30, 2014Assignee: Academia SinicaInventors: John Yu, Alice L. Yu, H. C. Wu, Sheng-Hung Wang, I-Ju Chen
-
Patent number: 8846861Abstract: A peptide clearing agent is provided for clearance of a conjugate of an enzyme and a binding molecule which binds specifically at a target location from a non-target location in a subject. The peptide clearing agent binds the active site of the enzyme. The peptide also binds to the asialoglycoprotein receptor expressed by hepatic cells to facilitate clearance through the liver. The peptide may be glycosylated to facilitate clearance through the liver by binding to hepatic cells expressing an asialoglycoprotein receptor. Typically, the peptide prevents or inhibits enzyme activity upon binding to the enzyme and is not substantially modified by the enzyme activity. The peptide may be based upon the dipeptide amino-naphthoic acid (ANA)-glutamate (GIu) and may comprise the amino acid sequence serine (Ser)-Alanine (Ala)-amino-naphthoic acid (ANA)-glutamate (GIu). In such cases, the enzyme of interest is typically CPG2.Type: GrantFiled: September 23, 2010Date of Patent: September 30, 2014Assignee: Mologic LtdInventors: Paul James Davis, James Alexander Schouten
-
Publication number: 20140286864Abstract: The present invention provides polypeptides, peptide dimer, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a KD<1 ?M), and dimer and multimeric constructs comprising these polypeptides.Type: ApplicationFiled: December 17, 2013Publication date: September 25, 2014Applicants: Bracco Suisse SA, Dyax Corp.Inventors: AARON K. SATO, DANIEL J. SEXTON, DANIEL T. DRANSFIELD, ROBERT CHARLES LADNER, CHRISTOPHE ARBOGAST, PHILIPPE BUSSAT, HONG FAN, SUDHA KHURANA, KAREN E. LINDER, EDMUND R. MARINELLI, PALANIAPPA NANJAPPAN, ADRIAN D. NUNN, RADHAKRISHNA K. PILLAI, SIBYLLE POCHON, KONDAREDDIAR RAMALINGAM, AJAY SHRIVASTAVA, BO SONG, ROLF E. SWENSON, MATHEW A. VON WRONSKI, FENG YAN
-
Publication number: 20140288000Abstract: Compositions and methods are disclosed that relate to novel plasmin-inhibiting polypeptides that are structural variants of a human TFPI-2 Kunitz-type proteinase first inhibitor domain (KD1). The polypeptides are potent plasmin inhibitors and in certain embodiments have anti-fibrinolytic activity and/or decreased anti-coagulation activity relative to wild-type TFPI-2 KD1 and are not highly immunogenic. The plasmin-inhibiting polypeptides will find uses as anti-cancer agents, as antifibrinolytic agents, as protease inhibitors, and in other contexts.Type: ApplicationFiled: March 14, 2014Publication date: September 25, 2014Applicant: The Regents of the University of CaliforniaInventor: S. Paul Bajaj
-
Publication number: 20140287984Abstract: The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.Type: ApplicationFiled: October 30, 2012Publication date: September 25, 2014Applicants: Bayer Pharmaaktiengesellschaft, Bayer Intellectual Property GMBHInventors: Ingo Flamme, Johannes Köbberling, Hans-Georg Lerchen, Nils Griebenow, Rudolf Schohe-Loop, Sven Wittrock, Maria Köllnberger, Frank Wunder, Gorden Redlich, Andreas Knorr, July Marley, Iain Pritchard
-
Publication number: 20140287994Abstract: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.Type: ApplicationFiled: March 17, 2014Publication date: September 25, 2014Applicant: The Regents of the University of CaliforniaInventors: John K. Bielicki, Jan Johansson, Waleed Danho
-
Publication number: 20140288007Abstract: The disclosure relates to compounds, peptides or peptidomimetics that inhibit, reduce or prevent protease activity and the use of these compounds, peptides or peptidomimetics to treat or prevent a condition. In particular the condition may be periodontal disease. The protease activity may be activity of a gingipain. The compounds, peptides or peptidomimetics of the invention may also be used in assays for the identification of protease inhibitors.Type: ApplicationFiled: November 2, 2012Publication date: September 25, 2014Applicant: Oral Health Australia Pty. Ltd.Inventors: Stuart Geoffrey Dashper, Eric Charles Reynolds, Noorjahan Laila Huq, Elena Chiew Yeen Toh
-
Publication number: 20140288005Abstract: An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat.Type: ApplicationFiled: May 27, 2014Publication date: September 25, 2014Applicant: Alphabeta ABInventor: Jan Johansson
-
Patent number: 8841253Abstract: The invention features methods for identifying compounds that inhibit cell death, and methods for identifying compounds that promote cell death, by blocking or accelerating, respectively, the translocation of the catalytic domain of toxins or transcription factors through the endosomal membrane into the cytosol of a cell. Also featured are methods for inhibiting cell death that include the administration of polypeptides that include a toxin consensus sequence recognized by one or more components of the cytosolic translocation factor complex.Type: GrantFiled: August 30, 2006Date of Patent: September 23, 2014Assignee: Boston Medical Center CorporationInventors: John R. Murphy, Ryan Ratts
-
Publication number: 20140271692Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: IMMATICS BIOTECHNOLOGIES GMBHInventors: Harpreet SINGH, Steffen WALTER, Toni WEINSCHENK, Norbert HILF, Oliver SCHOOR, Claudia TRAUTWEIN
-
Publication number: 20140271469Abstract: Disclosed are peptides comprising a molecular scaffold portion and a loop portion that binds to integrin ?v?6. This integrin is expressed on pancreatic tumors, making the peptides useful as imaging agents, among other uses. The peptides showed single-digit nanomolar dissociation constants similar to antibodies used clinically for imaging and therapy. The peptides rapidly accumulated in ?v?6-positive tumors, which led to excellent tumor-to-normal contrast. The peptides are specific for the targeted integrin ?v?6 receptors expressed on orthotopic pancreatic tumors and various xenografts used. Additionally, pharmacokinetic-stabilization strategies endowed knots with rapid renal clearance, which significantly reduced off-target dosing.Type: ApplicationFiled: May 21, 2014Publication date: September 18, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Richard H. Kimura, Sanjiv S. Gambhir, Benjamin J. Hackel, Robert Teed, Bin Shen, Frederick T Chin, Zhen Cheng
-
Publication number: 20140271723Abstract: The present invention relates to adjuvant compositions, vaccine compositions, and methods of enhancing an immune response to an antigen.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: Shuan Shian Huang, Jung San Huang
-
Publication number: 20140283207Abstract: The invention relates to novel nucleic acids and their encoded polypeptides from ASR and methods of use that enhance the plant's defensive elicitation response.Type: ApplicationFiled: March 13, 2013Publication date: September 18, 2014Applicant: E.I. DU PONT DE NEMOURS AND COMPANYInventors: Karen E. Broglie, Gregory J. Rairdan
-
Publication number: 20140274883Abstract: The subject invention pertains to novel biologically active extracts from marine algae and to biologically active fractions and components of these extracts. These extracts have been shown to possess antiviral properties. Pharmaceutical compositions comprising these extracts, or comprising biologically active fractions or components of these extracts, could be used in the treatment of viral diseases including influenza.Type: ApplicationFiled: March 24, 2014Publication date: September 18, 2014Applicants: UAB RESEARCH FOUNDATION, UNIVERSITY OF SOUTH FLORIDAInventors: Alberto VAN OLPHEN, Bill J. BAKER, Dennis E. KYLE, Cynthia BUCHER, Alan MASCHEK, James B. MCCLINTOCK, JR., Charles D. AMSLER
-
Publication number: 20140274906Abstract: The invention is based in part on identifying a core region of ND2 responsible for interacting with Src to within residues 289-321 of ND2 and more particularly residues 307-321 or 310-321 of ND2. Peptides including, overlapping or from within this region can be used to inhibit ND2 interaction with Src Inhibition of this interaction is useful for treatment or prophylaxis of neurological diseases and disorders, pain and cancer.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: NoNO Inc.Inventors: Michael Tymianski, Rongwen Li, Jonathan David Garman
-
Publication number: 20140275478Abstract: The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.Type: ApplicationFiled: March 17, 2014Publication date: September 18, 2014Applicant: Statens Serum InstitutInventors: Frank Follmann, Ida Rosenkrands, Anja Olsen, Peter Andersen
-
Publication number: 20140274755Abstract: A multi-transmembrane protein antigen includes a polypeptide corresponding to an extracellular loop of the multi-transmembrane protein, the N-terminal and C-terminal of the polypeptide being fixed on a solid substrate or the N-terminal and C-terminal being attached to both ends of a linker to form a cyclic structure, an antibody specifically binding to the antigen or an antigen-binding fragment thereof, and a method for screening an antibody specifically binding to the antigen. The present invention may be usefully employed for effective production of antibodies for multi-transmembrane proteins that play important roles in disease-related phenomena such as cell signaling.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: REFERENCE BIOLABS INC.Inventors: Young Kee SHIN, Young-Deug KIM, Jun Young CHOI, Myung Seok LEE
-
Publication number: 20140271652Abstract: Disclosed are immunomodulatory polypeptides that elicit an unusual induced cytokine profile, compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry. Pharmaceutical compositions and kits, and treatment methods are also disclosed.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Institute of Arthritis Research, LLCInventor: Craig D. Scoville
-
Publication number: 20140275477Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Applicant: CLARASSANCE, INC.Inventors: Aprile L. Pilon, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
-
Publication number: 20140274776Abstract: Porphyrin-modified antimicrobial peptides as described here may be used as indicators of the presence of microbial targets. Their application may be as (for example) (1) fluorescent indicators in a microarray format, (2) fluorescence or absorbance based indicators in traditional solution based applications, or (3) reflectance based indicators for use in reagent-less detection platforms.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: The Government of the United States of America, as represented by the Secretary of the NavyInventors: Chris Rowe Taitt, Brandy J. White
-
Publication number: 20140271700Abstract: Described herein are isolated polypeptides each containing one or more receptor-binding sites of toxin A (tcdA) of Clostridium difficile (Cd), nucleic acids encoding the polypeptides, and methods of using the polypeptides and nucleic acids.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Applicant: National Health Research InstitutesInventors: Pele Choi-Sing Chong, Jui-Hsin Huang, Chih-Hsiang Leng
-
Patent number: 8835601Abstract: This document provides natriuretic polypeptide delivery systems. For example, methods and materials related to natriuretic polypeptide delivery systems, methods and materials related to the use of such delivery systems to deliver natriuretic polypeptides to a mammal over a pro-longed period of time (e.g., weeks to months), and methods and materials related to treating heart failure conditions are provided.Type: GrantFiled: March 7, 2013Date of Patent: September 16, 2014Assignees: Mayo Foundation for Medical Education and Research, Nanyang Technological UniversityInventors: Horng H. Chen, John C. Burnett, Jr., Lim Soo Ghim, Subramanian S. Venkatraman